Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers
Authors:
- Akihiko OkuyamaAOAkihiko Okuyama
- Tetsuro KatoTKTetsuro Kato
Open Access
Abstract
BACKGROUND: A standard concept for the integration of surgery into the chemotherapy‐based treatment of patients with advanced germ cell carcinoma has been that surgery should be avoided in patients with serum tumor markers (α‐fetoprotein [AFP] and human chorionic gonadotropin [HCG]) that remain elevated. However, some patients may benefit from resection under such chemorefractory conditions. The objective of this retrospective study was to clarify the outcome and clinical prognostic variables of salvage surgery in patients with disseminated (AJCC Stage II or III) testicular germ cell carcinoma or extragonadal germ cell carcinoma who had elevated serum markers.METHODS: The authors reviewed the clinical records of 24 patients who underwent salvage surgery with elevated serum AFP and/or HCG levels after at least 3 courses of cisplatin‐based, systemic chemotherapy between January, 1985 and December, 2000. The survival rates were compared between the subgroups with regard to preoperative and postoperative clinical parameters using the Kaplan–Meier method and a Cox proportional hazards model.RESULTS: Ten of 24 patients (41.7%) were rendered free of disease and alive without disease after the surgery with or without adjuvant therapy at a median follow‐up of 74 months (range, 24–207 months). Among the preoperative parameters, high HCG levels were associated with significantly poorer survival (hazard ratio [HR], 8.321; 95% confidence interval [95% CI], 1.0753–64.553; P = 0.043 and P = 0.016, respectively; log‐rank test). In addition, patients who had visceral lesions at resection had a significantly poorer prognosis compared with patients who had retroperitoneal and/or mediastinal lymph node lesions (P = 0.038; log‐rank test). Among postoperative parameters, incomplete resection and persistently high HCG levels were associated significantly with poor survival, with a risk of death from disease of 12.516‐fold (95% CI, 1.786–87.781) and 9.311‐fold (95% CI, 1.796–48.256), respectively.CONCLUSIONS: Salvage surgery in patients with high serum tumors markers resulted in long‐term disease free status in approximately 40% of patients in a small subset with advanced germ cell carcinoma. Patients with elevated AFP levels alone (i.e., normal HCG levels) or with lymph node lesions alone seem to be good candidates for such surgery. Complete resection of target lesions and normalization of HCG levels after surgery are mandatory to achieve long‐term disease free status. Cancer 2003. © 2003 American Cancer Society.DOI 10.1002/cncr.11711Keywords
This publication has 19 references indexed in Scilit:
- Lectin-reactive alpha-Fetoprotein (AFP-L3%) Curability and Prediction of Clinical Course after Treatment of Non-seminomatous Germ Cell TumorsJapanese Journal of Clinical Oncology, 2002
- Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumorsCancer, 2002
- SALVAGE SURGERY OF CHEMOREFRACTORY GERM CELL TUMORS WITH ELEVATED TUMOR MARKERSJournal of Urology, 2000
- Results of Treatment After Relapse From High-Dose Chemotherapy in Germ Cell TumorsJournal of Clinical Oncology, 2000
- High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.Journal of Clinical Oncology, 1997
- Post-Chemotherapy Resection of Nonseminomatous Germ Cell Testicular Tumors Metastatic to the MediastinumJournal of Urology, 1996
- Surgical resection in patients withnonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapyUrology, 1994
- Surgical salvage of chemorefractory germ cell tumors.Journal of Clinical Oncology, 1993
- chemotherapy in non-seminomatous germ cell tumours: Outcome and importance of dose intensityEuropean Journal of Cancer, 1992
- VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors.Journal of Clinical Oncology, 1986